BMC Cancer (Feb 2007)

HNPCC <it>versus </it>sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression

  • Fleuren Gert,
  • Cornelisse Cees J,
  • van Puijenbroek Marjo,
  • Ferrone Soldano,
  • de Miranda Noel FCC,
  • Dierssen Jan,
  • van Wezel Tom,
  • Morreau Hans

DOI
https://doi.org/10.1186/1471-2407-7-33
Journal volume & issue
Vol. 7, no. 1
p. 33

Abstract

Read online

Abstract Background Abnormalities in Human Leukocyte Antigen (HLA) class I expression are common in colorectal cancer. Since HLA expression is required to activate tumor antigen-specific cytotoxic T-lymphocytes (CTL), HLA class I abnormalities represent a mechanism by which tumors circumvent immune surveillance. Tumors with high microsatellite instability (MSI-H) are believed to face strong selective pressure to evade CTL activity since they produce large amounts of immunogenic peptides. Previous studies identified the prevalence of HLA class I alterations in MSI-H tumors. However, those reports did not compare the frequency of alterations between hereditary and sporadic MSI-H tumors neither the mechanisms that led to HLA class I alterations in each subgroup. Methods To characterize the HLA class I expression among sporadic MSI-H and microsatellite-stable (MSS) tumors, and HNPCC tumors we compared immunohistochemically the expression of HLA class I, β2-microglobulin (β2m), and Antigen Processing Machinery (APM) components in 81 right-sided sporadic and 75 HNPCC tumors. Moreover, we investigated the genetic basis for these changes. Results HLA class I loss was seen more frequently in MSI-H tumors than in MSS tumors (p β2m and APM components genes. Conclusion HLA class I aberrations are found at varying frequencies in different colorectal tumor types and are caused by distinct genetic mechanisms. Chiefly, sporadic and hereditary MSI-H tumors follow different routes toward HLA class I loss of expression supporting the idea that these tumors follow different evolutionary pathways in tumorigenesis. The resulting variation in immune escape mechanisms may have repercussions in tumor progression and behavior.